Compare PubMatic Inc (PUBM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Sana Biotechnology Inc — how do they compare? PubMatic Inc trades at $18.67 (market cap $850.88M), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: PubMatic Inc and Sana Biotechnology Inc are close in size by market cap, and PubMatic Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Sana Biotechnology Inc for 23 Days on average.
| PUBM | SANA | |
|---|---|---|
Market Cap | $850.88M | $836.71M |
Volume | 997,698 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $19.18 | $5.92 |
52-Week Low | $6.28 | $2.68 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | $754.01M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $18.64, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock has beaten earnings estimates for the last three quarters, though it remains unprofitable with a negative net income margin. Recent news highlights strong Q2 2026 results, AI product adoption, and executive appointments, fueling positive sentiment.
The outlook is cautiously optimistic given analyst consensus and technical momentum, but risks include persistent profitability challenges and competitive pressures. Upside is supported by a $19.89 average price target, though investors should weigh high valuation multiples against earnings growth potential.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
